Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma

Natalie GalaninaThe University of Chicago Medical Center, Chicago, IL, USA;

Jagoda JasielecNorth Shore University Health System, Chicago, IL, USA;

David PeaceThe University of Illinois at Chicago, Chicago, IL, USA

Sonali M. SmithThe University of Chicago Medical Center, Chicago, IL, USA;

Chadi NabhanThe University of Chicago Medical Center, Chicago, IL, USA; Correspondence[email protected]

References

Zelenetz AD, Gordon LI, Wierda WG, et al. Diffuse large B-cell lymphoma version 1.2016. J Natl Compr Canc Netw. 2016;14:196–231.
PubMed Web of Science ®Google Scholar
Nabhan C, Kay NE. The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. Clinical medicine insights. Oncology. 2011;5:45–53.
PubMedGoogle Scholar
Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol. 2012;156:490–498.
PubMed Web of Science ®Google Scholar
Coiffier B, Radford J, Bosly A, et al. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol. 2013;163: 334–342.
PubMed Web of Science ®Google Scholar
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
PubMed Web of Science ®Google Scholar
Dunleavy K, Wilson WH. Appropriate management of molecular subtypes of diffuse large B-cell lymphoma. Oncology (Williston Park, NY). 2014;28:326–334.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date